SenzaGen AB

SenzaGen AB

SENZA · ST · Healthcare / Diagnostics & Research

4.47SEK-0.41 (-8.40%)

Price History

Full chart

Market Stats

Previous Close4.88
Open4.70
Day Range4.40 – 4.70
52-Week Range4.50 – 6.84
Volume81.74K
Market Cap146.94M
P/E (TTM)0.00
Forward P/E250.00
EPS-0.35
Dividend Yield0.00%
Beta0.60
50-Day Avg5.05
200-Day Avg5.39

About

SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, skin sensitization, and skin absorption; and eye irritation, phototoxicity, and cytotoxicity testing services and advisory services to pharma, medial devices, cosmetics, an chemical industries. Further, it provides SenzaGen, a test portfolio to assess toxicity of chemicals, cosmetics, medical devices, drug candidates, and nutrition/food additives. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Peter Nahlstedt
  • Employees34
  • HeadquartersBuilding 401, Lund, Sweden, 223 81, Sweden
  • Websitehttps://senzagen.com

Leadership

  • Mr. Peter NahlstedtPresident & CEO · b. 1974
  • Ms. Marianne OlssonVice President of Finance · b. 1961
  • Dr. Henrik JohanssonChief Scientist · b. 1982
  • Ms. Tina Dackemark LawessonVice President of Marketing & Communications · b. 1968
  • Mr. Andy ForrerydVice President of Sales · b. 1984
  • Ms. Helen OlssonVice President of HR · b. 1965

Financials

Income Statement

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.62M1.75M498.00K1.15M2.00M2.72M7.96M15.42M41.77M49.87M57.70M57.97M
Growth (%)-+7.64%-71.51%+131.53%+73.20%+36.40%+192.14%+93.79%+170.85%+19.39%+15.69%+0.48%
Cost of Revenue1.35M2.35M1.67M-9.16M-7.26M-776.00K5.01M5.97M14.43M14.94M19.10M20.41M
Gross Profit273.00K-607.00K-1.18M10.31M9.26M3.50M2.95M9.45M27.34M34.93M38.59M37.57M
Gross Margin16.81%-34.73%-235.94%894.10%463.45%128.49%37.09%61.30%65.44%70.05%66.89%64.80%
Operating Expense-161.00K4.28M10.16M26.91M29.99M41.43M30.05M40.99M47.53M49.67M57.54M49.07M
Operating Income434.00K-4.88M-11.34M-16.61M-20.73M-37.93M-27.10M-31.53M-20.19M-14.74M-18.95M-11.50M
Operating Margin26.72%-279.35%-2276.31%-1440.24%-1038.11%-1392.33%-340.51%-204.47%-48.34%-29.56%-32.84%-19.83%
EBITDA361.36K-4.60M-11.06M-15.99M-19.28M-34.75M-25.24M-27.08M-15.50M-13.75M-9.06M-7.30M
EBITDA Margin22.25%-262.93%-2220.68%-1387.16%-965.50%-1275.81%-317.17%-175.58%-37.10%-27.58%-15.71%-12.59%
Net Income262.00K-2.86M-8.94M-12.99M-16.09M-50.24M-27.32M-31.35M-24.91M-22.10M-17.85M-11.59M
Net Income Margin16.13%-163.44%-1795.58%-1126.97%-805.71%-1844.24%-343.24%-203.26%-59.64%-44.31%-30.94%-19.99%
R&D---5.87M5.79M10.84M2.63M3.87M8.98M3.75M7.09M3.66M
R&D as % of Total Revenue---508.76%290.14%397.76%33.00%25.12%21.51%7.51%12.29%6.31%
Interest Expense-94.00K54.00K30.00K1.00K1.00K147.00K19.00K189.00K37.00K477.00K1.25M
Interest Expense % of Total Revenue-5.38%10.84%2.60%0.05%0.04%1.85%0.12%0.45%0.07%0.83%2.15%

Balance Sheet

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.54M45.35M34.92M108.67M90.47M142.96M111.55M133.81M119.95M97.18M111.91M116.15M
Total Liabilities2.50M3.74M2.21M7.67M4.53M8.75M3.76M23.56M30.25M29.57M25.27M38.42M
Total Equity1.91M41.61M32.71M101.01M85.94M134.21M107.79M110.24M89.70M67.61M86.64M77.73M
Cash2.62M37.94M22.58M82.73M56.63M120.47M89.34M69.16M39.98M17.62M39.61M26.78M
Total Debt-1.50M-----2.26M1.31M1.67M1.78M28.65M
Net Debt-2.62M-36.44M-22.58M-82.73M-56.63M-120.47M-89.34M-68.45M-38.77M-15.95M-37.83M1.87M

Cash Flow

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.04M-6.28M-9.69M-11.65M-23.21M-31.08M-29.38M-20.98M-16.07M-16.45M-9.33M-7.05M
Investing Cash Flow-425.00K-2.45M-4.23M-9.56M-5.34M-3.61M-2.45M-26.55M-13.44M-6.08M-4.25M-6.03M
Financing Cash Flow1.50M44.05M-1.45M81.36M2.45M98.53M698.00K27.29M31.00K147.00K35.47M422.00K
Capital Expenditure0158.00K1.26M9.56M4.01M3.61M2.45M2.67M2.59M3.81M4.53M3.01M
Free Cash Flow1.04M-6.44M-10.95M-21.20M-27.22M-34.69M-31.82M-23.64M-18.66M-20.26M-13.86M-10.06M
FCF to OCF100.00%102.52%112.99%182.08%117.27%111.62%108.33%112.70%116.11%123.14%148.56%142.75%

Earnings

Report DateAug 4, 2016Feb 3, 2017Sep 29, 2017Mar 29, 2018Aug 22, 2018Feb 14, 2019Aug 22, 2019Feb 13, 2020Aug 20, 2020Feb 18, 2021Aug 19, 2021Feb 11, 2022Aug 18, 2022Feb 16, 2023Aug 24, 2023Nov 29, 2023Feb 14, 2024May 3, 2024Aug 15, 2024Nov 27, 2024Feb 13, 2025Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00---0.00------
EPS Actual-0.48-0.34-0.76-0.92-0.55-0.49-0.97-2.10-0.60-0.67-0.65-0.78-0.56-0.470.000.000.00-0.13-0.30-0.08-0.16-0.14-0.18-0.07-0.15-0.06-0.07
Surprise---------------------------
Timing-----------------Pre-market---------

Key Statistics & Ratios

Market Cap146.94M
Enterprise Value138.00M
Trailing P/E0.00
Forward P/E250.00
Price / Sales2.41
Price / Book1.74
EPS-0.35
Book Value2.77
Revenue (TTM)61.05M
Gross Profit (TTM)39.09M
EBITDA-1.80M
Profit Margin-15.15%
Operating Margin-13.84%
Return on Equity-11.13%
Return on Assets-4.76%
Shares Outstanding32.51M
Shares Float24.42M
Beta0.60
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%